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Abstract
Background: Active metabolism of peripheral blood mononuclear cells (PBMC) could suggest their suitability for
metabolomics studies. This study examined whether reductions in PBMCs and plasma lipoprotein-associated
phospholipase A2 (Lp-PLA2) activities induced by dietary intervention affected the overall metabolic profiles of
PBMC and plasma.
Methods: Eighty nonobese subjects aged 40–70 years (18.5≤ BMI < 30 kg/m2) with prediabetes or newly-diagnosed
type-2 diabetes were assigned to consume either the usual refined-rice diet (control group, n = 40) or to replace
refined rice with whole grains and legumes as carbohydrates (whole-grain group, n = 40) for three meals per day
during the 12-week intervention. Fasting PBMC and plasma metabolomes were profiled using UPLC-LTQ-Orbitrap
mass spectrometry.
Results: After 12 weeks, changes in fasting glucose, HbA1c, HOMA-IR, MDA, ox-LDL, LDL particle size, plasma Lp-PLA2
activity, and PBMC enzyme activity in the whole-grain group were significantly different from those in the control
group before and after adjusting for baseline levels. The PBMC levels of L-leucine, oleamide, lysoPC (16:0), and lysoPC
(18:0) in the whole-grain group showed greater reductions compared with those of the control group. Changes in
plasma metabolites were not significantly different between the two groups. Changes in PBMC Lp-PLA2 activity
positively correlated with changes in L-leucine, oleamide, lysoPC (16:0), lysoPC (18:0), glucose, and ox-LDL, and
negatively correlated with changes in LDL particle size.
Conclusions: This study showed that dietary intervention in prediabetic or type-2 diabetic patients had a greater effect
on PBMC Lp-PLA2 activity and metabolites compared with those of plasma metabolites.
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Background
Diabetes is an epidemic metabolic disorder; about 2.7
million Korean people (8.03 %) aged 30 years or older
had type-2 diabetes (T2D) and 25.0 % of adults had pre-
diabetes in 2013 according to Korean Diabetes Fact
Sheet 2015. Diabetes-related mortality was steadily de-
creased since 2003 and ranked as the fifth leading cause of
natural death [1]. Prediabetes can be indicated by either
impaired fasting glucose (IFG) by the American Diabetes
Association criteria [2] or impaired glucose tolerance
(IGT) by World Health Organization criteria [3].
Lipoprotein-associated phospholipase A2 (Lp-PLA2)
independently predicts T2D incidence and may be in-
volved in its etiology [4]. In recent study, an inverse as-
sociation was observed between protein intake and
circulating Lp-PLA2 activity, suggesting that nutritional
factors may influence Lp-PLA2 activity [5]. An interven-
tion study that replaced refined rice with whole grains
and legumes reduced blood glucose, insulin, Lp-PLA2
activity, and cardiovascular risk factors in patients with
prediabetes or T2D [6]. The effects of this intervention
diet on plasma and peripheral blood mononuclear cell
(PBMC) metabolites have not been determined.
PBMCs include monocytes and lymphocytes which are
blood cells having a round nucleus. These blood cells
are a critical component in the immune system to fight
infection and adapt to intruders. Monocytes have a key
role in onset and development of inflammatory reactions
by generating bioactive molecules such as Lp-PLA2 in
response to inflammatory stimuli [7]. Lymphocytes are
consist of three major types; T cells, B cells, and natural
killer cells. T cells and B cells are the major cellular
components of the adaptive immune response, whereas
natural killer cells are a part of the innate immune sys-
tem. The production and release of Lp-PLA2 by lympho-
cytes may become increased under inflammatory
conditions [8]. Dietary intervention induces PBMC gene
expression changes, including downregulating genes in-
volved in inflammatory processes [9]. Therefore, changes
in PBMC metabolites and Lp-PLA2 activity after dietary
intervention could reflect dynamic responses, which are
not detectable in plasma metabolomics analyses. The aim
of this 12-week intervention study was to examine
whether reductions in PBMC and plasma Lp-PLA2 activ-
ities induced by dietary intervention (replacement of re-
fined rice with whole grains and legumes, and higher
intake of vegetables) affected the overall metabolic profiles
of PBMC and plasma in nonobese patients that exhibited
IFG, IGT, or newly-diagnosed T2D.
Methods
Subjects and study design
Nonobese subjects aged 40–70 years (18.5 ≤ BMI <
30 kg/m2) were recruited from the Health Service Center
(HSC) at the Ilsan Hospital, Goyang, Korea, during
January–June 2013. Based on the HSC data, subjects
who had IFG (100 ≤ fasting glucose <126 mg/dL) or
newly-diagnosed T2D (fasting glucose ≥126 mg/dL) were
referred to the Department of Family Medicine or Internal
Medicine. Exclusion criteria included: current and/or past
history of cardiovascular disease; liver or kidney dysfunc-
tion; thyroid or pituitary disease. Subjects who were taking
medications or supplements also were excluded. A total of
82 subjects were enrolled. The macronutrient composition
of each subject’s usual diet corresponded to a typical diet
with cooked refined rice. The purpose of the study was
carefully explained to all participants, and written consent
was obtained prior to their participation. The Institutional
Review Board of the NHIC-sponsored Ilsan Hospital and
Yonsei University provided ethical approval of the study
protocol, which was performed according to the Helsinki
Declaration.
The present study was performed in two phases, includ-
ing a 2-week run-in phase consisting of the usual diet with
refined rice, and a 12-week intervention phase. During the
run-in period, two subjects who did not maintain their en-
ergy intake dropped out. The remaining 80 subjects were
randomly subdivided into the two study groups, and were
assigned to consume either the usual refined-rice diet
(control group, n = 40) or to replace refined rice with
whole grains and legumes as carbohydrates (whole-grain
group, n = 40) for three meals per day during the 12-week
intervention.
Assessment of dietary intake and physical activity level
All subjects were given written and verbal instructions
by a registered dietitian on completion of a 3-day
(2 week days and 1 weekend day) dietary record every
2 weeks throughout the study. On the dietary record
sheet, subjects were instructed to weigh and record the
food amount before and after ingestion. All participants
were advised to continue their usual refined-rice diet
during a 2-week run-in period. Baseline measurements
were performed at the start of the run-in phase. After a
run-in period, subjects in the control group maintained
the usual refined-rice diet, whereas subjects in the whole-
grain group replaced refined rice with a mix of 1/3 le-
gumes, 1/3 barley, and 1/3 wild rice three times per day,
and increased vegetable intake to at least 6 units
(30–70 g/unit) per day for sufficient dietary fiber in-
take. The dietitian monitored subject compliance and
body-weight changes during the whole study by perform-
ing biweekly visits or telephone interviews and all partici-
pants were encouraged to maintain their usual lifestyles.
Dietary energy values and nutrient contents from 3-day
food records were calculated using the CAN-pro 3.0
(Korean Nutrition Society, Seoul, Korea). Total energy
expenditures (kcal/day) were calculated from activity
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patterns including basal metabolic rate, physical activity
for 24 h [10], and specific food dynamic action. Basal
metabolic rate for each subject was calculated with the
Harris–Benedict equation [11].
Anthropometry and blood pressure analysis
Body weight and height of unclothed subjects without
shoes were measured in the morning for calculating
body mass index (BMI, kg/m2). Waist circumference
was measured on standing subjects at the umbilical level
after normal expiration. Blood pressure (BP) of seated
subjects after a 20-min rest was measured in the left arm
with an automatic BP monitor (FT-200S, Jawon Medical,
Gyeongsan, Korea). After a 12-h fasting period, venous
blood specimens were collected in EDTA-treated and
plain tubes and centrifuged to yield plasma or serum, re-
spectively, which were stored at −70 °C until analysis.
Clinical measurements
Fasting total cholesterol and triglyceride levels were ana-
lyzed using a Hitachi 7600 Autoanalyzer (Hitachi Ltd.,
Tokyo, Japan). ApoB-containing lipoproteins were pre-
cipitated with dextran-magnesium sulfate, and high
density lipoprotein (HDL)-cholesterol concentrations in
patient serum samples were measured enzymatically. For
subjects with serum triglyceride levels <400 mg/dL, low
density lipoprotein (LDL)-cholesterol concentrations
were estimated indirectly using the Friedewald formula.
For subjects with serum triglyceride levels ≥400 mg/dL,
LDL-cholesterol concentrations were measured directly.
Free fatty acids (FFA) were analyzed using the acyl-CoA
synthetase − acyl-CoA oxidase enzymatic assay method
and a Hitachi 7600 Autoanalyzer.
All subjects underwent an oral glucose-tolerance test
at 0 and 12 weeks by ingesting a 75 g glucose solution
after a 12-h overnight fast. Venous specimens were col-
lected before glucose loading, at loading, and 30, 60, and
120-min after loading to determine serum glucose levels
and responses. Fasting glucose levels were analyzed by the
hexokinase method using a Hitachi 7600 Autoanalyzer.
Insulin levels were measured using an immunoradio-
metric assay kit from DIAsource ImmunoAssays S.A.
(Louvain, Belgium). Hemoglobin A1c (HbA1c) was mea-
sured by immonoturbidimetric analysis. Insulin resistance
(IR) was calculated by the homeostasis-model assessment
(HOMA) [12].
Whole blood was mixed with the same volume of RPMI
1640 (Gibco, Life Technologies, Gland Island, NY) and
gently laid on a histopaque-1077 (Sigma-Aldrich, St.
Louis, MO). The sample was then centrifuged at
1800 rpm for 20-min at 10 °C. After the separation, a thin
layer of PBMCs was isolated and washed twice with RPMI
1640. The pellet was resuspended in RPMI 1640 with
streptomycin. Isolated PBMCs were cultured in RPMI
1640 supplemented with 10 % fetal bovine serum (FBS),
seeded in 12-well plates (1x106 cells/mL; SPL, Gyeonggi-do,
Korea), and incubated at 37 °C with 5 % CO2 for 22.5 h.
After a 22.5 h incubation, 10 % FBS was added and incu-
bated for 24.5 h. At third day, PBMC supernatants were
collected and stored at −80 °C until Lp-PLA2 activity
levels were assayed. Lp-PLA2 activity in plasma and
PBMC supernatants was measured by using a modifica-
tion of a previously described high-throughput radiomet-
ric activity assay [13].
Serum high-sensitivity C-reactive protein (hs-CRP) was
measured with an ADVIA 2400 Clinical Chemistry System
(Siemens Ltd., Tarrytown, NY) using a commercially avail-
able, hs-CRP-Latex(II) X2 kit (Denka-Seiken Co., Ltd.,
Tokyo, Japan). Plasma malondialdehyde (MDA) was mea-
sured from thiobarbituric acid − reactive substances
(TBARS) using the TBARS Assay Kit (ZeptoMetrix Co.,
Buffalo, NY). LDL particles were isolated by sequential
flotation ultracentrifugation, and particle size distribution
(1.019–1.063 g/mL) was examined using a pore-gradient
lipoprotein system (CBS Scientific Company, San Diego,
CA) on commercially available, non-denaturing gels
containing a linear 2–16 % acrylamide gradient (CBS
Scientific Company). Latex-bead (30 nm) conjugated
thyroglobulin (17 nm), ferritin (12.2 nm), and catalase
(10.4 nm) standards were used to estimate the relative
band migration rates. Gels were scanned using a GS-800
Calibrated Imaging Densitometer (Bio-Rad Laboratories,
Hercules, CA). Plasma oxidized (ox)-LDL was measured
using an enzyme immunoassay (Mercodia AB, Uppsala,
Sweden), and the resulting color reaction was determined
at 450 nm on a Wallac Victor2 multilabel counter (Perkin-
Elmer Life Sciences, Boston, MA).
Global (nontargeted) metabolic profiling of PBMC and
plasma
PBMC and plasma extract sample preparation
Before analysis, 800 μL of 80 % acetonitrile was added to
100 μL of PBMC and plasma, mixed by vortexing, and
centrifuged at 10,000 rpm for 5-min at 4 °C. The super-
natant was dried with N2 (l), dissolved in 10 % methanol,
mixed by vortexing, and centrifuged at 10,000 rpm for
5-min at 4 °C. The supernatant was transferred into a vial.
Ultra performance liquid chromatography
PBMC and Plasma extract samples (4 μL) were injected
into an Acquity UPLC-BEH-C18 column (2.1 × 50 mm,
1.7 μm; Waters, Milford, MA) that was coupled in-line with
a UPLC-LTQ-Orbitrap XL (Thermo Fisher Scientific,
Waltham, MA). The injected samples were equilibrated
with water containing 0.1 % formic acid. Samples were
eluted with an acetonitrile gradient containing 0.1 % formic
acid at a flow rate of 0.35 mL/min for 20-min. Metabolites
were separated by UPLC, analyzed, and assigned by LTQ-
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Orbitrap-XL. The mass spectrometer (MS) was operated in
ESI-positive mode. The spray voltage was 5 kV. The flow-
rate nitrogen sheath gas and the auxiliary gas were 50 and
5 (arbitrary units). The capillary voltage (V), tube-lens volt-
age (V), and capillary temperature (°C) were kept constant
at 35 V, 80 V, and 370 °C. Orbitrap data were collected in
the range of m/z 50–1,000. MS/MS spectra of metabolites
were obtained by a collision-energy ramp from 55–65 eV,
and conducted with Xcalibur 2.1 and MS Frontier software
(Thermo Fisher Scientific).
Data processing and identification of metabolites
All MS data including retention times, m/z, and ion in-
tensities were extracted by SIEVE software (Thermo
Fisher Scientific) incorporated into the instrument, and
the resulting MS data were assembled into a matrix.
SIEVE parameters were set as follows: m/z range 50–
1,000; m/z width 0.02; retention time width 2.5; and m/z
tolerance 0.005. Metabolites were searched using the
following databases: ChemSpider (www.chemspider.com),
Human Metabolome (www.hmdb.ca), Lipid MAPS
(www.lipidmaps.org), KEGG (www.genome.jp/kegg), and
MassBank (www.massbank.jp). Selected metabolites were
confirmed by retention times and mass spectra of stand-
ard samples.
Statistical analyses
Statistical analyses were performed using SPSS v. 21.0
(IBM SPSS Statistics 21, Chicago, IL). Skewed variables
were logarithmically transformed for statistical analyses.
A two-tailed P-value of <0.05 was considered statistically
significant. Differences in biochemical variables between
two groups at baseline and follow-up were tested using
Student’s independent t-test. General linear model tests
were applied to compare parameter changes between the
two groups by adjusting for baseline values. Paired t-tests
were used to evaluate differences between baseline and
follow-up levels in each group. Pearson’s and partial
correlation coefficients were used to examine the relation-
ships between variables over time. False discovery rate −
corrected q-values were computed using the R package
‘fdrtool’. Heat map was created to visualize and evaluate
correlations among metabolites and conventional risk fac-
tors in study populations.
Multivariate statistical analysis was performed using
SIMCA-P+ software version 12.0 (Umetrics, Umeå,
Sweden). Partial least-squares discriminant analysis
(PLS-DA) was used as the classification method for
modeling the discrimination between groups by visualiz-
ing the score scatter plot or S-plot using the first and
second PLS components. The goodness-of-fit was quan-
tified by R2Y, whereas the predictive ability was quanti-
fied by Q2Y. Generally, R2Y describes how well the data
in the training set were mathematically reproduced and
varied between 0 and 1 (a value of 1 indicated a model
with a perfect fit). Models with Q2Y ≥0.5 were consid-
ered to have good predictive capabilities.
Results
Clinical characteristics, lipid profiles, and nutrient intake
There were no significant differences between two
groups in baseline characteristics including age, gender,
smoking, and drinking (data not shown). At baseline,
there were no significant differences between two groups
in BMI, waist:hip ratio (WHR), systolic BP, diastolic BP,
serum triglyceride, total cholesterol, LDL-cholesterol,
HDL-cholesterol, FFA, and hs-CRP. BMI, WHR, BP,
serum lipid profiles, hs-CRP, total energy expenditure,
and total energy intake were similar before and after the
study in both groups (data not shown).
Replacement with whole grains and legumes caused
significant increase in percent energy intake of protein
and fat, and significant decrease in percent energy intake
of carbohydrate. The percent energy intake of protein,
fat, and carbohydrate significantly differed between the
two groups before adjusting for baseline values. The
whole-grain group had significant increases in fiber in-
take and polyunsaturated-to-saturated fatty acids ratio
compared with baseline values. After 12-week, the
whole-grain group had lower percent energy of carbohy-
drate, higher percent calorie of protein and fat, and fiber
intake than control group (Table 1).
Fasting glucose, insulin, and malondialdehyde
At the end of the study, glucose, HbA1c, and MDA con-
centrations significantly increased in the control group,
whereas glucose, glucose AUC (area under the curve),
HbA1c, HOMA-IR, insulin, and MDA significantly de-
creased in the whole-grain group (Table 1). Changes in
glucose, glucose AUC, HbA1c, HOMA-IR, and MDA in
the whole-grain group were significantly different from
those in the control group before and after adjusting for
baseline levels. Post-treatment glucose, HOMA-IR, and
MDA in the whole-grain group were significantly lower
than those in the control group (Table 1).
Plasma ox-LDL, LDL particle size, Lp-PLA2 activity in
plasma and unstimulated PBMC
At the end of the study, the whole-grain group had
lower ox-LDL and Lp-PLA2 activity in PBMC and larger
LDL particle size, whereas the control group had higher
Lp-PLA2 activity in PBMC (Table 1). These changes in
ox-LDL, LDL particle size, plasma Lp-PLA2 activity, and
PBMC Lp-PLA2 activity in the whole-grain group were
significantly different from those in the control group
before and after adjusting for baseline levels. The post-
treatment whole-grain group had lower ox-LDL and
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PBMC Lp-PLA2 activity, and larger LDL particle size
than control group (Table 1).
Metabolic profiling of PBMC and plasma using UPLC-LTQ-
orbitrap MS
Nontargeted metabolic pattern analysis
MS data of PBMC and plasma metabolites obtained at
baseline and follow-up were analyzed with PLS-DA
score scatter plot for the following two combinations: 1)
control and whole-grain groups at baseline, control
group at follow-up, and whole-grain group at follow-up
(Fig. 1a, PBMC; Fig. 1c, plasma); and 2) control and
whole-grain groups at follow-up (Fig. 1b, PBMC; Fig. 1d,
plasma). The PBMC metabolite PLS-DA score scatter
plot showed distinct clustering and clear separation for
the following subjects: control and whole-grain groups
at baseline, control group at follow-up, and whole-grain
group at follow-up [R2X(cum) = 0.124, R2Y(cum) = 0.34,
Q2Y(cum) = 0.218] (Fig. 1a). These distinct clusters indicate
that PBMC profiling detects metabolic changes induced by
dietary intervention. The PBMC metabolite PLS-DA score
scatter plot showed distinct clustering for control and
whole-grain groups at follow-up [R2X(cum) = 0.125,
R2Y(cum) = 0.809, Q2Y(cum) = 0.525] (Fig. 1b).
The plasma metabolite PLS-DA score scatter plot were
not as clearly clustered as those for PBMC metabolites
[R2X(cum) = 0.124, R2Y(cum) = 0.376, Q2Y(cum) = 0.127]
(Fig. 1c). For control and whole-grain groups at follow-up,
the plasma metabolite PLS-DA score scatter plot were not
as clearly clustered as those for PBMC metabolites
[R2X(cum) = 0.201, R2Y(cum) = 0.704, Q2Y(cum) = 0.414]
(Fig. 1d). To identify metabolites that differentially
Table 1 Biochemical characteristics and estimates of daily nutrient intake before and after 12-week dietary intervention
Control group (n = 40) Whole-grain group (n = 40) Pa Pb Pc Pd
Baseline Follow-up Baseline Follow-up
Glucose (mg/dL)∮ 119.8 ± 5.40 126.6 ± 6.02*** 119.4 ± 5.31 110.0 ± 4.58*** 0.958 0.005
Change 6.78 ± 1.51 −9.45 ± 1.43 <0.001 <0.001
Glucose AUC (mg/dL × h)∮ 376.8 ± 17.7 390.4 ± 22.9 376.6 ± 18.9 352.0 ± 17.5* 0.923 0.225
Change 13.6 ± 9.52 −24.7 ± 8.75 0.004 0.004
HbA1c (%)
∮ 6.46 ± 0.19 6.60 ± 0.19* 6.41 ± 0.18 6.18 ± 0.15* 0.821 0.061
Change 0.14 ± 0.06 −0.23 ± 0.12 0.007 0.003
HOMA-IR∮ 2.24 ± 0.15 2.34 ± 0.17 2.18 ± 0.12 1.79 ± 0.12*** 0.791 0.006
Change 0.10 ± 0.11 −0.39 ± 0.10 0.002 0.001
Insulin (μIU/mL)∮ 7.58 ± 0.35 7.47 ± 0.43 7.58 ± 0.43 6.72 ± 0.46** 0.798 0.132
Malondialdehyde (nmol/mL)∮ 9.24 ± 0.53 10.2 ± 0.61*** 9.41 ± 0.39 8.70 ± 0.37** 0.530 0.041
Change 0.98 ± 0.24 −0.71 ± 0.24 0.001 <0.001
Oxidized LDL (U/L)∮ 49.1 ± 2.14 50.7 ± 2.26 48.2 ± 2.01 43.8 ± 2.00*** 0.846 0.036
Change 1.65 ± 0.90 −4.41 ± 0.82 0.001 <0.001
LDL particle size (nm)∮ 24.1 ± 0.12 24.1 ± 0.13 24.4 ± 0.15 24.6 ± 0.17*** 0.214 0.015
Change −0.05 ± 0.06 0.24 ± 0.05 0.001 0.001
Plasma Lp-PLA2 activity (nmol/mL/min)
∮ 30.1 ± 1.64 30.3 ± 1.61 28.0 ± 1.20 25.7 ± 1.11 0.874 0.701
Change 0.24 ± 0.41 −2.38 ± 0.55 0.001 <0.001
Unstimulated PBMCLp-PLA2 activity (nmol/mL/min)
∮ 2.00 ± 0.12 2.28 ± 0.13** 2.16 ± 0.12 1.90 ± 0.12** 0.365 0.046
Change 0.28 ± 0.08 −0.26 ± 0.10 0.001 <0.001
Estimate of daily nutrient intake
Energy intake (kcal/d) 2,143 ± 40 2,170 ± 38 2,166 ± 36 2,185 ± 38 0.665 0.786
Carbohydrate (%) 61.9 ± 0.16 61.9 ± 0.17 61.9 ± 0.17 54.6 ± 0.11 0.833 <0.001
Protein (%) 16.3 ± 0.10 16.3 ± 0.08 16.3 ± 0.10 20.5 ± 0.13 0.851 <0.001
Fat (%) 22.1 ± 0.16 22.2 ± 0.15 22.1 ± 0.16 24.9 ± 0.15 0.731 <0.001
Crude fiber (g)∮ 25.2 ± 1.20 22.8 ± 1.19 24.5 ± 1.21 28.4 ± 1.18 0.713 0.001
PUFA/SFA 2.10 ± 0.18 2.10 ± 0.16 2.29 ± 0.16 2.98 ± 0.17 0.418 <0.001
Mean ± SEM.∮tested by logarithmic transformation, Pa, values derived from independent t-test in baseline. Pb, values derived from independent t-test in follow-up.
Pc, values derived from independent t-test in changed value. Pd, values derived from independent t-test in changed value after adjusting for baseline. *P < 0.05,
**P < 0.01, ***P < 0.001 derived from paired t-test. PBMC, peripheral blood mononuclear cell; AUC, area under the curve; PUFA/SFA, polyunsaturated-to-saturated
fatty acids ratio
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determined data at baseline and follow-up, S-plots of
p(1) and p(corr) (1) were generated using centroid
scaling. The S-plots revealed that metabolites with
higher or lower p(corr) values more clearly discrimi-
nated between the two groups.
Identification of PBMC metabolites
Of 1,923 PBMC metabolites, those that correlated with
separation between the groups were identified by the
variable important in the projection (VIP) parameter;
VIP values >1.0 were highly relevant for group differ-
ences. 51 metabolites had VIP >1.0; 10 of these were
previously identified and 41 were unknown. Those 10
PBMC metabolites at baseline and follow-up are shown
in Table 2. There were no significant differences in base-
line metabolites between two groups. After follow-up,
the control group showed significant changes in six
PBMC metabolite levels, whereas the whole-grain group
showed significant changes in seven PBMC metabolite
levels (Table 2).
We compared PBMC metabolite changes between two
groups. The whole-grain group had greater reductions in
L-leucine (q = 0.031), oleamide (q = 0.032), lysoPC (16:0)
(q = 0.003), and lysoPC (18:0) (q = 0.003) (Table 2). At
follow-up, the whole-grain group had higher peak inten-
sities of L-pyroglutamic acid and ribothymidine, and
lower peak intensities of palmitic amide, oleamide, and
lysoPCs, compared with those of the control group
(Table 2).
Identification of plasma metabolites
Of 4,121 plasma metabolites, those that correlated with
separation between the groups were selected by VIP >1.0.
122 plasma metabolites were selected; 20 were previously
identified and 102 were unknown (Table 3). There were
no significant differences in baseline between two groups.
After follow-up, C17 sphinganine significantly increased
in the control group, also, there were no significant differ-
ences in metabolites between two groups, and no signifi-
cant differences in metabolite changes with respect to
baseline (Table 3).
Correlations among fasting glucose, plasma and PBMC
Lp-PLA2 activities, biochemical parameters, and major
PBMC metabolites
The correlation matrix of changes in glucose, Lp-PLA2
activities in plasma and PBMC, biochemical parameters,
and major PBMC metabolites was computed (Fig. 2).
Baseline
Whole grain group at 12-week follow-up
Control group at 12-week follow-up

















































































a b c d
Fig. 1 Identification of PBMC and plasma metabolites that were significantly altered at 12-week follow-up. a Partial least squares discriminant
analysis score scatter plot (PLS-DA score scatter plot) of PBMC metabolites at baseline (n = 80), whole-grain group at follow-up (n = 40), and
control group at follow-up (n = 40). b PLS-DA score scatter plot of PBMC metabolites for whole-grain group at follow-up (n = 40) and control
group at follow-up (n = 40). c PLS-DA PLS-DA score scatter plot of plasma metabolites at baseline (n = 80), whole-grain group at follow-up
(n = 40), and control group at follow-up (n = 40). d PLS-DA score scatter plot of plasma metabolites for whole-grain group at follow-up (n = 40)
and control group at follow-up (n = 40)
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Normalized peak intensity Variable important in the projection
Control group (n = 40) Whole-grain group (n = 40) Baseline vs. follow-up 12-weeks
Baseline Follow-up Baseline Follow-up Control Whole-grain Control vs. whole-grain
Cyclopentanone dimethylhydrazone C7H14N2 127.1235 82,551 ± 21,507 101,931 ± 26,693
* 43,192 ± 11,728 51,504 ± 14,505* 0.0722 0.1523 1.0119
L-Pyroglutamic acid C5H7NO3 130.0504 2,410,045 ± 108,001 2,075,511 ± 48,362
* 2,455,521 ± 70,667 2,484,381 ± 103,907†† 0.1241 3.9771 2.6550
L-Leucine C6H13NO2 132.1025 7,884,178 ± 309,297 7,922,462 ± 251,819 8,253,845 ± 170,803 7,531,331 ± 171,144
** 1.8209 3.1661 5.0363
Change 38,283 ± 198,486 −722,514 ± 145,341‡
L-Phenylalanine C9H11NO2 166.0868 2,880,509 ± 113,266 2,755,872 ± 75,646 2,825,355 ± 101,371 2,761,323 ± 56,360 0.5962 0.6567 1.1474
Dihydrobiopterin C9H13N5O3 239.1018 432,360 ± 23,845 335,279 ± 14,924
*** 427,487 ± 16,797 383,280 ± 15,727* 0.4537 1.2616 0.4680
Palmitic amide C16H33NO 256.2640 354,492 ± 50,930 330,909 ± 44,809 490,272 ± 84,177 172,851 ± 26,551
**,† 2.7281 0.1468 2.0394
Ribothymidine C10H14N2O6 258.0930 302,320 ± 22,108 239,902 ± 12,851
** 322,971 ± 16,498 311,114 ± 19,898† 0.0730 0.5966 1.3107
Oleamide C18H35NO 282.2797 2,676,408 ± 412,881 3,257,688 ± 511,380 3,697,245 ± 621,193 1,491,246 ± 235,475
*,† 18.4793 8.3202 22.5845
Change 581,279 ± 634,410 −2,205,998 ± 651,404‡
LysoPC(16:0) C24H50NO7P 496.3403 414,438 ± 44,544 645,199 ± 57,544
* 549,155 ± 59,016 383,399 ± 35,718*,†† 2.7864 2.8925 3.5066
Change 230,762 ± 72,860 −165,756 ± 63,955‡‡
LysoPC(18:0) C26H54NO7P 524.3716 285,044 ± 26,648 423,718 ± 34,129
** 364,186 ± 33,732 262,585 ± 23,409*,†† 1.5197 1.7796 2.0579
Change 138,674 ± 40,222 −101,601 ± 42,602‡‡
Mean ± SEM. *q < 0.05, **q < 0.01, ***q < 0.001 derived from paired t-test. †q < 0.05, ††q < 0.01, †††q < 0.001 derived from independent t-test in follow-up. ‡q < 0.05, ‡‡q < 0.01, ‡‡‡q < 0.001 derived from changed values be-


















Normalized peak intensity Variable important in the projection
Control group (n = 40) Whole-grain group (n = 40) Baseline vs. follow-up 12-weeks
Baseline Follow-up Baseline Follow-up Control Whole-grain Control vs.
whole grain
L-Valine C5H11NO2 118.0868 1,338,114 ± 39,666 1,323,676 ± 36,213 1,328,470 ± 41,793 1,376,655 ± 34,768 0.7807 0.1901 1.0144
L-Leucine C6H13NO2 132.1025 3,130,607 ± 99,839 3,098,031 ± 98,593 3,130,777 ± 107,368 3,166,315 ± 85,278 0.4904 0.5781 0.7853
L-Phenylalanine C9H11NO2 166.0868 1,984,169 ± 49,821 1,914,567 ± 45,393 1,997,467 ± 84,582 1,975,319 ± 41,491 0.6137 1.1072 0.7382
Oleamide C18H35NO 282.2797 11,074,949 ± 815,519 11,182,173 ± 1,054,856 11,348,184 ± 805,164 12,102,398 ± 709,965 8.4316 19.2720 6.6270
C17 Sphinganine C17H37NO2 288.2903 323,013 ± 20,549 441,137 ± 24,748
* 333,258 ± 29,775 355,950 ± 25,250 0.9135 1.3462 0.1114
(4E,8E,10E-d18:3) Sphingosine C18H33NO2 296.2590 420,731 ± 59,507 832,979 ± 152,996 608,061 ± 81,037 754,737 ± 66,758 1.5120 8.8050 2.2736
Anandamide (18:4, n-3) C20H33NO2 320.2590 170,194 ± 28,584 237,343 ± 31,518 209,059 ± 26,262 213,643 ± 16,101 0.1156 1.4954 0.5840
LysoPC (14:0) C22H46NO7P 468.3090 480,474 ± 33,898 503,684 ± 38,015 625,962 ± 45,904 537,767 ± 45,983 1.5352 0.7142 0.2242
LysoPC (16:1) C24H48NO7P 494.3247 1,133,250 ± 77,052 1,033,013 ± 69,288 1,261,066 ± 78,064 1,127,811 ± 88,549 2.3243 1.4177 1.0354
LysoPC (16:0) C24H50NO7P 496.3403 15,953,932 ± 573,566 15,910,457 ± 684,453 16,830,932 ± 686,817 15,967,767 ± 537,944 15.3974 7.7607 4.7470
LysoPC (17:0) C25H52NO7P 510.3560 689,578 ± 58,089 710,335 ± 73,384 758,848 ± 49,685 733,637 ± 53,343 0.5841 1.3389 0.1217
LysoPC (18:3) C26H48NO7P 518.3247 620,814 ± 20,714 591,900 ± 19,836 658,460 ± 22,577 675,799 ± 31,645 0.1217 0.3985 1.1643
LysoPC (18:2) C26H50NO7P 520.3403 6,388,637 ± 262,115 6,025,486 ± 300,959 6,617,717 ± 260,021 6,878,238 ± 274,508 2.2535 4.8170 15.1889
LysoPC (18:1) C26H52NO7P 522.3560 5,375,808 ± 229,038 5,364,828 ± 250,194 5,593,899 ± 214,117 5,425,134 ± 241,245 4.2976 3.7059 4.2779
LysoPC (18:0) C26H54NO7P 524.3716 5,661,866 ± 195,118 5,610,496 ± 261,241 5,976,007 ± 255,107 5,830,224 ± 224,489 2.5863 3.3556 5.4463
LysoPC (20:5) C28H48NO7P 542.3247 771,884 ± 61,530 784,374 ± 53,112 997,008 ± 89,800 876,925 ± 59,723 2.1218 0.4055 1.2595
LysoPC (20:4) C28H50NO7P 544.3403 2,512,566 ± 118,266 2,294,343 ± 118,562 2,188,892 ± 126,719 1,958,744 ± 83,560 2.9839 3.3959 6.5629
LysoPC (22:6) C30H50NO7P 568.3403 1,268,789 ± 89,205 1,160,444 ± 72,253 1,322,936 ± 96,792 1,153,481 ± 79,319 1.8183 1.6819 0.2714
SM (d18:0/16:1) C39H79N2O6P 703.5754 918,463 ± 110,095 628,987 ± 81,863 1,046,537 ± 118,533 1,088,608 ± 142,939 0.9346 4.2113 7.9088
Lactosylceramide (d18:1/12:0) C42H79NO13 806.5630 5,977,825 ± 630,100 8,134,712 ± 703,408 6,832,476 ± 741,718 5,908,934 ± 712,523 4.8718 8.3007 5.9197
1PCs 44,523,937 ± 2,514,233 44,154,177 ± 1,968,873 43,454,754 ± 2,366,214 50,137,749 ± 2,118,552
Mean ± SEM. *q < 0.05, **q < 0.01, ***q < 0.001 derived from paired t-test. †q < 0.05, ††q < 0.01, †††q < 0.001 derived from independent t-test in follow-up. ‡q < 0.05, ‡‡q < 0.01, ‡‡‡q < 0.001 derived from changed values













Analysis of metabolic changes including all subjects
identified the following correlations: glucose correlated
positively with insulin, HOMA-IR, plasma Lp-PLA2 ac-
tivity (r = 0.454, P < 0.001), MDA, ox-LDL, Lp-PLA2 in
PBMC (r = 0.511, P < 0.001), glucose AUC, C-peptide,
HbA1c, and PBMC lysoPCs after adjusting for age, gender,
BMI, smoking, and drinking. After adjusting for confound-
ing variables, plasma Lp-PLA2 activity correlated positively
with glucose, HOMA-IR, ox-LDL, Lp-PLA2 activity in
PBMC (r = 0.516, P < 0.001), glucose AUC, PBMC palmitic
amide, and PBMC oleamide. After adjusting for confound-
ing variables, PBMC Lp-PLA2 activity correlated positively
with glucose, HOMA-IR, plasma Lp-PLA2 activity, ox-
LDL, PBMC L-leucine, PBMC oleamide, PBMC lysoPCs,
and correlated negatively with LDL particle size (Fig. 2).
Discussion
We identified four PBMC metabolites that had statistically
significant differences after dietary intervention, including
L-leucine, oleamide, lysoPC (16:0), and lysoPC (18:0); how-
ever, there were no significant differences in plasma metab-
olites after dietary intervention. These aspects of results
were also shown in both subjects with prediabetes and
T2D, respectively. PBMCs may be a useful tool for
nutrigenomics and understanding the pathophysiology of
chronic disease due to their active metabolism [14, 15].
These results identify PBMC metabolites as powerful meta-
bolomics tools to detect diet-induced metabolic changes.
Improving glycemic control in the whole-grain group
decreases ox-LDL, and reduces PBMC Lp-PLA2 activity
and PBMC lysoPCs. A strong correlation between
PBMC Lp-PLA2 activity and ox-LDL, but not LDL-
cholesterol, is consistent with a previous report of a dir-
ect effect of ox-LDL on Lp-PLA2 expression in THP-1
monocytes [16]. Ox-LDL may upregulate PBMC Lp-
PLA2 expression in smokers [17]. Ox-phospholipids in
LDL particles are hydrolyzed by Lp-PLA2 at the sn-2
position to produce bioactive ox-FFAs and lysoPCs.
Only 1 − 5 % of the total non-ox-LDL PC content is
lysoPC; however, up to 40 − 50 % of LDL PC is con-
verted to lysoPC during LDL oxidation [18]. This study
identified strongly positive correlations among ox-LDL,
PBMC Lp-PLA2 activity, PBMC lysoPCs, which may in-
dicate that ox-LDL and PBMC Lp-PLA2 activity are
major determinants of PBMC lysoPC levels.
A negative correlation between PBMC Lp-PLA2 activ-
ities, PBMC lysoPCs with LDL particle size is consistent
with a previous report of Lp-PLA2 binding preference
Fig. 2 Correlation matrix for changes in biochemical characteristics and PBMC metabolites in total subjects. Supervised hierarchical clustering
identifies the most important 10 metabolites and 9 biochemical characteristics. Correlations were obtained by deriving Spearman correlation
coefficients. Red, positive correlation. Purple, negative correlation
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for small dense LDL [19]. This study and other work [6]
reported positive correlations among glucose, PBMC Lp-
PLA2 activity, and plasma Lp-PLA2 activity. A strongly
positive correlation between PBMC and plasma Lp-PLA2
activities also is observed in healthy subjects [17, 20]. In a
porcine diabetes model, PBMC Lp-PLA2 expression is up-
regulated in the presence of glycation end products [21].
Increases in circulating Lp-PLA2 activity and increased
ox-LDL levels in hypercholesterolemic pigs are primarily
due to plaque macrophages [22]. These results indicate
that the primary sources of plasma Lp-PLA2 are plaque
macrophages [22] and PBMC [17]. This could explain our
observations of lower plasma Lp-PLA2 activity changes
compared with that of PBMC Lp-PLA2 activity, and no
significant differences in plasma metabolite changes be-
tween two groups.
Reduced Lp-PLA2 activity in plasma and PBMC in the
whole-grain group could be a marker of metabolic
changes induced by increased consumption of protein
relative to carbohydrate. Diet composition is an import-
ant factor in inflammatory processes of blood cells [23].
A study of macronutrient composition determined that
increasing dietary protein from 19 % energy intake to
30 % yielded immediate and persistent downregulation
of immunological genes in PBMCs [9]. Replacing 5 % of
energy from carbohydrates with energy from protein and
measured a 2.2 nmol/min/mL reduction in Lp-PLA2 ac-
tivity that was independent of other changes in lipid pro-
files [5]. Our study replaced 7 % of energy from
carbohydrate with approximately 4 % energy from pro-
tein and 3 % energy from fat.
Whole grains, legumes, and vegetables contain many
antioxidants, vitamins, minerals, and phytochemicals
[24, 25]. Antioxidants slow the oxidation rate of reduced
substrates [24, 26]. Soybean phytochemicals reduce lipid
peroxidation in vivo and attenuate LDL oxidation [27].
Our observed changes in glucose and HOMA-IR strongly
correlated with changes in MDA and ox-LDL in patients
with prediabetes or T2D, consistent with a previous report
[28]. We observed positive correlation between changes in
HOMA-IR and PBMC L-leucine, but not plasma L-
leucine. This may be due to a negligible effect of
PBMC L-leucine on plasma L-leucine, or the 12-week
dietary intervention may not be long enough to
change plasma L-leucine. The whole-grain group also
had greater reduction in PBMC oleamide, but not in
plasma, compared with control group. We identified
PBMC oleamide (VIP = 22.5845) as the most important
metabolite for evaluating differences between two groups
at the end of the study. Recently, Ha et al. [29] identified
plasma oleamide as the most important metabolite for dis-
tinguishing nondiabetic from diabetic males. Therefore,
positive correlations between changes in PBMC oleamide,
Lp-PLA2, PBMC palmitic amide, and PBMC lysoPCs
observed in our study could be partly due to dietary-
induced effects on blood cell inflammatory processes [23].
This study detected many metabolic markers using
UPLC-LTQ-Orbitrap MS, but most are currently uniden-
tified. Endogenous biomolecule databases for use with
LC-MS − based metabolomics research are still under
construction [30]. Despite this limitation, UPLC-LTQ-
Orbitrap MS metabolomics and multivariate data analysis
identified greater reductions in PBMC L-leucine, PBMC
oleamide, PBMC lysoPCs in the whole-grain group than
control group; however, there were no significant differ-
ences in plasma metabolites between two groups.
Conclusion
This study demonstrates that replacing refined rice with
whole grains and legumes induced greater differences in
PBMC Lp-PLA2 activity and metabolites than in plasma
metabolites in nonobese patients with prediabetes or
newly-diagnosed T2D. Therefore, consumption of minim-
ally refined grains, legumes, and vegetables should be rec-
ommended to control glucose metabolism and reduce
cardiovascular risk factors in patients with IFG, IGT, or
newly-diagnosed T2D.
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